Skip to main content
Caplight Logo









IAMA Therapeutics

IAMA Therapeutics

Private
GenoaHealthcare & Life Scienceshttps://iamatherapeutics.com/

Last Round

Series B

Apr 16, 2025

Total Funding Raised

$25.83M

Company Overview

IAMA Therapeutics is a biotechnology company that develops a neuroscience drug discovery platform to provide personalized treatments for patients suffering from untreatable neurological conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall molecule therapeuticsCNS disorderscentral nervous systemion channel inhibitorspreclinical drug developmentbiopharmaepilepsy treatmentautism spectrum disordersdrug out-licensingcomputational drug designCADDneurotherapeuticspharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IAMA Therapeutics Comparables

Compare IAMA Therapeutics with similar companies based on industry and business-model similarity.

IAMA Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Axonis Therapeutics
81%
GRIK Therapeutics
80%
Actio Biosciences
79%

IAMA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 16, 2025
Series AMar 29, 2022

Key People

Founding team and executive leadership

Torsten M. Madsen

Chief Executive Officer

Executive Team

IAMA Therapeutics Investors

Notable investors and investment history

IAMA Therapeutics investors
InvestorRounds
Indaco Venture Partners SGRSeries B
Claris VenturesSeries A, Series B
Cassa Depositi e PrestitiSeries A, Series B
CDP Venture Capital SGRSeries B, Series A
ENEA-Tech and Biomedical FoundationSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 18, 2025

    Torsten M. Madsen appointed as the new Chief Executive Officer.

  • Sep 1, 2025

    Torsten M. Madsen was dismissed in September 2025.

IAMA Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

IAMA Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about IAMA Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersGenoa
Employee Range12
Year Founded2021
Last FundingApr 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?